Digoxin (DIG) is a cardiac drug given to treat patients with congestive heart failure, angina and arrythmias. This drug must be monitored in patients to allow proper dose adjustment and prevent toxicity. Digoxin concentrations should be measured at least eight hours after an oral dose and ideally when concentrations have reached steady state.
Enzyme Immunoassay, Chemiluminescence
Competitive Assay, Streptavidin-Coated Plate
0, 0.25, 0.5, 1, 2, 4 ng/ml
September 24, 2010 Advisory:
Monobind has upgraded Digoxin to a HRP-based system which uses a
streptavidin plate. Effective Oct 2010, all shipments will include this
new format. Please see new IFU on ELISA page.